Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon α-2a (PEGASYS)

被引:150
作者
Foser, S
Schacher, A
Weyer, KA
Brugger, D
Dietel, E
Marti, S
Schreitmüller, T
机构
[1] F Hoffmann La Roche & Co Ltd, Biotech Dev & Prod, Biotech Prod, Dept Pharma Tech Operat Biotechnol, CH-4070 Basel, Switzerland
[2] F Hoffmann La Roche & Co Ltd, Biotech Prod, Dept Pharma Res Discovery Struct, CH-4002 Basel, Switzerland
[3] F Hoffmann La Roche & Co Ltd, Biotech Prod, Dept Analyt Dev & Qual Control, CH-4002 Basel, Switzerland
关键词
interferon alpha-2a; pegylation; forty kilodaltons of branched polyethylene glycol; separation of positional isomers; antiviral effect;
D O I
10.1016/S1046-5928(03)00055-X
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Interferon alpha-2a plays an essential role in the treatment of chronic hepatitis C, but it is limited in its efficacy by the short in vivo half-life. To improve the half-life and efficacy, interferon alpha-2a is conjugated with a 40-kDa branched polyethylene glycol moiety (PEG-IFN, PEGASYS). From this preparation the positional PEG-IFN isomers were isolated and characterized by different analytical methods and antiviral assay. Two chromatographic steps were used to separate and purify nine isomers. The analytical methods IE-HPLC, RP-HPLC, SE-HPLC, SDS-PAGE, and MALDI-TOF MS indicated that each of these nine isomers is conjugated to the branched polyethylene glycol chain at a specific lysine. No isomer with a modification at the amino terminus was observed. All positional isomers induced viral protection of MDBK cells in the antiviral assay. When comparing the quantitative potency of the individual isomers with the whole mixture of PEG-IFN, significant differences in the specific activities were observed: PEG-Lys(31) and PEG-Lys(134) showed higher activities than the mixture, PEG-Lys(164) was equal to the mixture, whereas the activities of PEG-Lys(49), PEG-Lys(70), PEG-Lys(83), PEG-Lys(112), PEG-Lys(121), and PEG-Lys(131) were lower. (C) 2003 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:78 / 87
页数:10
相关论文
共 23 条
[1]   Rational design of a potent, long-lasting form of interferon:: A 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C [J].
Bailon, P ;
Palleroni, A ;
Schaffer, CA ;
Spence, CL ;
Fung, WJ ;
Porter, JE ;
Ehrlich, GK ;
Pan, W ;
Xu, ZX ;
Modi, MW ;
Farid, A ;
Berthold, W .
BIOCONJUGATE CHEMISTRY, 2001, 12 (02) :195-202
[2]  
BAILON P, 1997, Patent No. 0809996
[3]   TIME COURSE OF INTERFERON LEVELS, ANTIVIRAL STATE, 2',5'-OLIGOADENYLATE SYNTHETASE AND SIDE-EFFECTS IN HEALTHY-MEN [J].
BAROUKI, FM ;
WITTER, FR ;
GRIFFIN, DE ;
NADLER, PI ;
WOODS, A ;
WOOD, DL ;
LIETMAN, PS .
JOURNAL OF INTERFERON RESEARCH, 1987, 7 (01) :29-39
[4]   Pegylation - A novel process for modifying pharmacokinetics [J].
Harris, JM ;
Martin, NE ;
Modi, M .
CLINICAL PHARMACOKINETICS, 2001, 40 (07) :539-551
[5]   Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis [J].
Heathcote, EJ ;
Shiffman, ML ;
Cooksley, WGE ;
Dusheiko, GM ;
Lee, SS ;
Balart, L ;
Reindollar, R ;
Reddy, RK ;
Wright, TL ;
Lin, A ;
Hoffman, J ;
De Pamphilis, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (23) :1673-1680
[6]  
JORDAN CH, 2002, BIOCHEMISTRY-US, V41, P3575
[7]   The three-dimensional high resolution structure of human interferon α-2a determined by heteronuclear NMR spectroscopy in solution [J].
Klaus, W ;
Gsell, B ;
Labhardt, AM ;
Wipf, B ;
Senn, H .
JOURNAL OF MOLECULAR BIOLOGY, 1997, 274 (04) :661-675
[8]  
Lamb MW, 2002, ANN PHARMACOTHER, V36, P933
[9]  
Lavanchy D, 1999, J VIRAL HEPATITIS, V6, P35
[10]   Positional isomers of monopegylated interferon alpha-2a: Isolation, characterization, and biological activity [J].
Monkarsh, SP ;
Ma, YM ;
Aglione, A ;
Bailon, P ;
Ciolek, D ;
DeBarbieri, B ;
Graves, MC ;
Hollfelder, K ;
Michel, H ;
Palleroni, A ;
Porter, JE ;
Russoman, E ;
Roy, S ;
Pan, YCE .
ANALYTICAL BIOCHEMISTRY, 1997, 247 (02) :434-440